Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1(A)/V2 receptor antagonist

Folia Pharmacologica Japonica

Volumn 114, Issue SUPPL. 1, 1999, Pages 113-117

  Yatsu, Takeyuki ^a   Tomura, Yuichi ^a   Tahara, Atsuo ^a   Wada, Koh Ichi ^a   Kusayama, Toshiyuki ^a   Tsukada, Junko ^a   Tanaka, Akihiro ^a   Iizumi, Yuichi ^a   Honda, Kazuo ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Congestive heart failure; Hyponatremia; V1(A) V2 receptor antagonist; Vasopressin; YM087

Indexed keywords

CONIVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG RESEARCH; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

EID: 0032755258     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.114.supplement_113     Document Type: Article

References (16)

1. Laszlo FA, Laszlo F and De Wied D: Pharmacology and clinical perspectives of vasopressin antagonist. Pharmacol Rev 43, 73-108 (1991)
2. Bouby N, Bachmann S, Bichet D and Bankir L: Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258, F973-979 (1990)
3. Francis GS: Neuroendocrine manifestations of congestive heart failure. Am J Cardiol 62, 9A-13A (1988)
4. Parmley WW: Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 13, 771-785 (1989)
5. 1 receptor agonist, in a canine model of acute congestive heart failure. Gen Pharmacol 30, 733-737 (1998)
6. Packer M: Treatment of chronic heart failure. Lancet 340, 92-95 (1992)
7. Goldsmith SR, Francis GS and Cowley AW Jr: Arginine vasopressin and the renal response to water loading in congestive heart failure. Am J Cardiol 58, 295-299 (1986)
8. Lee WH and Packer M: Pronostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patient with severe chronic heart failure. Circulation 73, 257-67 (1986)
9. Manning M. and Sawyer WH: Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 114, 617-632 (1989)
10. 2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 282, 301-308 (1997)
11. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W and Tanaka A: Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol 125, 1463-1470 (1998)
12. Cheng Y and Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC) of an enzymatic reaction. Biochem Pharmacol 22, 3099-3108 (1973).
13. Tomura Y, Tahara A, Tsukada J, Yatsu T, Uchida W, Iizumi Y and Honda K: Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats. Clin Exp Pharmacol Physiol 26, 399-403 (1999)
14. 2 receptor antagonist, in dogs. Eur J Pharmacol 321, 225-230 (1997)
15. 2 receptor antagonist, in dogs with pacing-induced congestive heart failure. Eur J Pharmacol 376, 239-246 (1999)
16. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W and Tanaka A: Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 38, 198-205 (1998)